TRV GP IV, LLC
Long book
$266.9M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
+22.8%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsTRV GP IV, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $266.9M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: MAZE THERAPEUTICS INC, TANGO THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 8.1pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-2.0%
Q2 2024
-10.9%
Q3 2024
-43.7%
Q4 2024
-67.6%
Q1 2025
+75.9%
Q2 2025
+85.1%
Q3 2025
+36.7%
Q4 2025
+16.9%
Q1 2026
+22.8%
Sector allocation
Healthcare 100%
Long book by quarter
What does TRV GP own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 7, 2026 | 2 | $266.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 2 | $255.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 2 | $274.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 8, 2025 | 3 | $163.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 9, 2025 | 3 | $92.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 2 | $80.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 6, 2024 | 3 | $162.1M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 9, 2024 | 3 | $202.2M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 13, 2024 | 3 | $206.4M | canonical | SEC ↗ |